Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 4NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Dermatologic 4Other hematologic neoplasm 3Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1CNS 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cytarabine 117Cyclophosphamide 88Etoposide 59Daunorubicin 58fludarabine phosphate 50Specimen Handling 49Methotrexate 49Filgrastim 48Vincristine 47Biopsy 47Rituximab 43Radiotherapy 34Dexamethasone 34Peripheral Blood Stem Cell Transplantation 32Doxorubicin 29Mitoxantrone 27Idarubicin 27Busulfan 27Azacitidine 27Prednisone 26Mercaptopurine 26Leucovorin 26fludarabine 25Decitabine 24Asparaginase 24venetoclax 23merphos 22Bortezomib 22Cyclosporine 20alvocidib 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Interleukin-15 × Other hematologic neoplasm × Clear all
NCT04185220 2023-01-04

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
6 enrolled 16 charts
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 13 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡